What is Lassogen?
Lassogen, Inc. is at the forefront of biopharmaceutical innovation, specializing in the creation of programmable medicines inspired by natural biological mechanisms. The company's core technology revolves around the optimization of lasso peptides, leading to the development of therapeutics known as Lassotides. These novel agents are designed to emulate the therapeutic advantages of both antibodies and small molecules, offering a potential solution for challenging diseases that are currently underserved by existing treatments. Lassogen's scientific endeavors are supported by a seasoned team possessing extensive collective experience in the biotech and pharmaceutical sectors, positioning the company to address a wide spectrum of disease indications with its unique modality.
How much funding has Lassogen raised?
Lassogen has raised a total of $4.5M across 1 funding round:
Angel/Seed
$4.5M
Angel/Seed (2020): $4.5M with participation from Better Ventures, Playground Global LLC, Foothill Ventures, and First In Ventures
Key Investors in Lassogen
Better Ventures
Better Ventures is a mission-driven venture capital firm that invests in early-stage startups focusing on leveraging science and technology to create a sustainable economy that benefits people and the planet. Their investment themes include sustainable industry, improving human health, and equipping tomorrow's workforce, all aimed at addressing significant global challenges.
Playground Global LLC
Playground Global LLC is an investment firm that typically focuses on early-stage technology companies. Their involvement suggests an interest in Lassogen's innovative approach to medicine and its potential for disruptive impact in the healthcare sector.
Foothill Ventures
Foothill Ventures is an investment firm that supports companies with significant growth potential. Their participation in Lassogen's funding round indicates confidence in the company's therapeutic platform and its ability to address unmet medical needs.
What's next for Lassogen?
The recent major strategic investment signals a pivotal growth phase for Lassogen, likely enabling the company to accelerate its research and development pipeline, advance its Lassotide therapeutics through clinical trials, and potentially expand its operational capacity. This infusion of capital is expected to bolster Lassogen's efforts in tackling complex diseases, reinforcing its position as a key innovator in the programmable medicines space. The company's focus on a unique therapeutic modality, combined with substantial financial backing, suggests a strategic push towards commercialization and broader market impact.
See full Lassogen company page
